HOLLISTON, Mass., Oct. 2, 2017 /PRNewswire/ -- Biostage Inc.,
(Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology
company developing bioengineered organ implants to treat congenital
defects, cancers and other life-threatening conditions of the
esophagus, bronchus and trachea, announced today that Saverio La
Francesca, MD, President and Chief Medical Officer of Biostage,
will present at the 2017 Cell & Gene Meeting on the Mesa on
Thursday, October 5th at 4:45PM PDT in La Jolla,
CA. Members of the executive management team will also
participate in one-on-one meetings during the conference.
Dr. La Francesca will provide a medical and scientific review as
well as outline the Company's expected upcoming near-term
corporate, clinical and regulatory milestones that will enable
Biostage's transition to a clinical-stage company.
A live video webcast of the presentation will be available on
the Events page of the Investors section of the Company's website
(www.biostage.com).
About the Cell & Gene Meeting on the
Mesa
Organized by ARM and the Sanford Stem Cell Clinical
Center at UC San Diego, the Cell & Gene Meeting on the Mesa is
a three-day conference featuring three distinct parts, the
program's two-day Partnering Forum, a Public Forum lecture and a
full-day Scientific Symposium. The event's Partnering Forum on
October 4-5, features more than 70
dedicated company presentations in addition to 90 panelists and
featured speakers.
Please visit http://www.meetingonthemesa.com for full
information including registration. Complimentary attendance at
this event is available for credentialed investors and members of
the media only. Investors should contact Laura Parsons at lparsons@alliancerm.org and
interested media should contact Lyndsey
Scull at lscull@alliancerm.org.
About Biostage
Biostage is a biotechnology company
developing bioengineered organ implants based on the Company's
Cellframeā¢ technology which combines a proprietary biocompatible
scaffold with a patient's own stem cells to create Cellspan organ
implants. Cellspan implants are being developed to treat
life-threatening conditions of the esophagus, bronchus or trachea
with the hope of dramatically improving the treatment paradigm for
patients. Based on its preclinical data, Biostage has selected
life-threatening conditions of the esophagus as the initial
clinical application of its technology.
For more information, please visit www.biostage.com and connect
with the Company on Twitter and LinkedIn.
Forward-Looking Statements:
Some of the statements in
this press release are "forward-looking" and are made pursuant to
the safe harbor provision of the Private Securities Litigation
Reform Act of 1995. These "forward-looking" statements in this
press release include, but are not limited to, statements relating
to the private placement, any rights offerings, development
expectations and regulatory approval of any of our products,
including those utilizing our Cellframe technology, by the U.S.
Food and Drug Administration, the European Medicines Agency or
otherwise, which closings, offerings, expectations or approvals may
not be achieved or obtained on a timely basis or at all; or success
with respect to any collaborations, clinical trials and other
development and commercialization efforts of our products,
including those utilizing our Cellframe technology, which such
success may not be achieved or obtained on a timely basis or at
all. These statements involve risks and uncertainties that may
cause results to differ materially from the statements set forth in
this press release, including, among other things, our ability to
obtain and maintain regulatory approval for our products and our
ability to complete the private placement on a timely basis or at
all; plus other factors described under the heading "Item 1A. Risk
Factors" in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2016 or described in our other public
filings. Our results may also be affected by factors of which we
are not currently aware. The forward-looking statements in this
press release speak only as of the date of this press release.
Biostage expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to such statements to
reflect any change in its expectations with regard thereto or any
changes in the events, conditions or circumstances on which any
such statement is based.
Investor Relations
Contacts:
|
|
Tom
McNaughton
|
|
Chief Financial
Officer
|
|
774-233-7300
|
|
tmcnaughton@biostage.com
|
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/biostage-to-present-at-the-2017-cell--gene-meeting-on-the-mesa-300528511.html
SOURCE Biostage Inc.